<DOC>
	<DOCNO>NCT00536016</DOCNO>
	<brief_summary>The purpose study determine way rate study medication , JSM6427 potent , highly specific integrin α5β1-antagonist absorbed , broken-down eliminate body give single dosage strength injection eye . Repeated dosage also give determine high safe dose .</brief_summary>
	<brief_title>A Phase 1 Safety Study Single Repeated Doses JSM6427 ( Intravitreal Injection ) Treat AMD</brief_title>
	<detailed_description>In non-clinical model , JSM6427 lead inhibition regression choroidal neovascularization , make α5β1 attractive target therapeutic strategy direct pathological angiogenesis . JSM6427 may also interfere key process pathogenesis AMD , namely inflammation fibrosis . Further , non-clinical data show JSM6427 inhibit scar inflammation . Thus , JSM6427 may target multiple important pathway pathogenesis neovascular AMD .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Best correct visual acuity study eye 5 7 letter inclusive use ETDRS chart ( Snellen equivalent appx . 20/800 20/40 . Subfoveal choroidal neovascularization ( CNV ) due AMD . Total area lesion ( include blood , neovascularization scar/atrophy ) must ≤ 12 DA , least 25 % must active CNV . For patient occult non classic CNV ; must presence subretinal hemorrhage ( still comprise 50 % lesion ) and/or document evidence three line vision loss ( ETDRS equivalent ) previous 12 week . Clear ocular medium adequate pupillary dilatation permit good stereo fundus photography screening . Intraocular pressure 21 mm Hg le . Retinal thickness ≥ 250 μm OCT. Normal screen ERG Normal ECG PDT within 120 day prior screen study eye . Previous therapeutic radiation eye . Any retinovascular disease retinal degeneration AMD . Serous pigment epithelial detachment without presence neovascularization . Presence pigment epithelial tear rip . Previous posterior vitrectomy retinal surgery . Any periocular infection past 4 week . Concomitant therapy antiVEGF therapy , e.g . Avastin , Lucentis Macugen , previous use agent within 60 day screen study eye . Concomitant therapy intravenous intravitreous corticosteroid use within 90 day screen . Cataract surgery study eye within three month screen . Intraocular surgery study eye within three month screen . Presence ocular infection study eye . Presence severe myopia ( 8 diopter great ) study eye . Allergy prior significant adverse reaction fluorescein . Any major surgical procedure within one month trial entry .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>AMD</keyword>
	<keyword>Neovascular Age-Related Macular Degeneration</keyword>
</DOC>